GlassScriptPhysician profile
Edward G Stiles
NPI 1649318221
$420.24
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was more than what a typical Neuromusculoskeletal Medicine & Omm provider received nationally (typical 2025 total: $119).
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $117 · 2024: $148 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $92.96 | 2023-2024 | |
| Lilly USA, LLC | $82.06 | 2023-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $45.32 | 2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $33.51 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.17 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $22.97 | 2025 | Jynarque |
| Atricure, INC. | $22.00 | 2025 | Atriclip Laa Exclusion System |
| Travere Therapeutics, INC. | $17.30 | 2024 | |
| Glaxosmithkline, LLC. | $15.85 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $15.21 | 2023 | |
| Calliditas Therapeutics US INC. | $13.66 | 2024 | |
| Xeris Pharmaceuticals, INC. | $13.15 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $13.08 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Stiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.